OMIC Singular Genomics Systems Inc

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2024

 

 

Singular Genomics Systems, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware			001-40443	81-2948451
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
3010 Science Park Road San Diego, California 92121

 

(858) 333-7830 (Registrant’s address of principal executive offices and telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		OMIC		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

---

 

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2024, Singular Genomics Systems, Inc. (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended September 30, 2024. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit Number		Description
99.1		Press Release dated November 12, 2024.
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

 

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Singular Genomics Systems, Inc.
Dated:	November 12, 2024	By:	/s/ Dalen Meeter
			Dalen Meeter Chief Financial Officer Principal Financial Officer and Principal Accounting Officer

 

---

 

Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

 

San Diego, CA, November 12, 2024 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2024.

 

“In the third quarter, we made significant progress in the development of the G4X spatial sequencer,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. “We are encouraged by the interest in the G4X and validation received through the expansion of our Spatial Technology Access Services project funnel, which reinforces our confidence in the potential for the G4X to deliver high-throughput spatial sequencing and multiomics at a superior value for our customers.”

 

Recent Updates

 

Third Quarter 2024 Financial Results

 

Revenue for the third quarter of 2024 was $0.4 million, driven primarily by consumables sales. Revenue from instrument shipments during the third quarter is expected to be generated over time as these customers purchase consumables.

Gross profit was negative $0.3 million in the third quarter of 2024, compared to negative $0.1 million in the third quarter of 2023. Gross margin was negatively impacted by the company’s use of reagent rental and other non-capital purchase instrument placements, as well as higher costs associated with the support of system placements, which was partially offset by higher margins on consumable sales.

Total operating expenses for the third quarter of 2024 were $17.8 million, compared to $24.5 million for the third quarter of 2023. Operating expenses included non-cash stock-based compensation of $2.2 million for the third quarter of 2024, and $2.8 million for the third quarter of 2023. Operating expenses in the third quarter of 2024 were partially offset by a non-cash gain of $1.6 million on lease modification for the partial termination of a lease agreement.

Net loss for the third quarter of 2024 was $16.8 million, or a loss of $6.72 per common share, compared to $22.4 million, or a loss of $9.25 per common share, in the third quarter of 2023.

Cash, cash equivalents and short-term investments, excluding restricted cash, as of September 30, 2024 totaled $113.8 million.

Due to ongoing discussions related to a potential strategic transaction, the company will not host a conference call to discuss its third quarter results. For further details regarding the company’s financial performance, please refer to its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2024 available on the company’s website at www.singulargenomics.com or at www.sec.gov.

---

About Singular Genomics Systems, Inc.

Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4® Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In addition, the company is currently developing the G4X™ Spatial Sequencer, which will leverage its proprietary sequencing technology, applying it as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.

 

Forward-looking Statements

 

Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. In some cases, forward-looking statements can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “foresees,” “forecasts,” “guidance,” “intends” “goals,” “may,” “might,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “targets,” “will,” “would” or similar expressions and the negatives of those terms. These forward-looking statements are subject to risks, uncertainties and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Further information on these and additional risks that could affect Singular Genomics’ results is included in its filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and future reports that Singular Genomics may file with the SEC from time to time, which could cause actual results to vary from expectations. Any forward-looking statement made by Singular Genomics in this press release speaks only as of the day on which Singular Genomics makes it. Singular Genomics assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release.

 

Investor Contact

Philip Trip Taylor

Gilmartin Group

ir@singulargenomics.com

 

Media Contact

Matt Browning

pr@singulargenomics.com

---

Singular Genomics Systems, Inc.

Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

 

	Three Months Ended September 30,								Nine Months Ended September 30,
	2024				2023				2024				2023
Revenue	$	406			$	462			$	1,586			$	1,830
Cost of revenue		707				527				2,483				1,931
Gross margin		(301	)			(65	)			(897	)			(101	)
Operating expenses:
Research and development		9,568				11,220				31,790				36,074
Selling, general and administrative		8,202				13,254				35,036				41,345
Total operating expenses		17,770				24,474				66,826				77,419
Loss from operations		(18,071	)			(24,539	)			(67,723	)			(77,520	)
Other income (expense):
Interest income		1,562				2,464				5,506				6,763
Interest expense		(286	)			(285	)			(856	)			(814	)
Total other income		1,276				2,179				4,650				5,949
Net loss	$	(16,795	)		$	(22,360	)		$	(63,073	)		$	(71,571	)
Net loss per share:
Basic and diluted net loss per share	$	(6.72	)		$	(9.25	)		$	(25.41	)		$	(29.73	)
Weighted-average shares used to compute basic and diluted net loss per share		2,501,093				2,417,001				2,481,956				2,407,276

 

---

Singular Genomics Systems, Inc.

Balance Sheets

(In thousands, except share and par value amounts)

 

		September 30,				December 31,
		2024				2023
		(Unaudited)
Assets
Current assets:
Cash and cash equivalents		$	52,620			$	16,233
Short-term investments			61,213				157,708
Accounts receivable			183				565
Inventory, net			12,410				13,572
Prepaid expenses and other current assets			3,384				4,150
Total current assets			129,810				192,228
Right-of-use lease assets			42,617				57,797
Property and equipment, net			12,457				13,692
Restricted cash			600				600
Other noncurrent assets			1,067				1,150
Total assets		$	186,551			$	265,467
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	1,882			$	2,587
Accrued expenses			4,887				6,079
Lease liabilities, current			5,469				7,764
Other current liabilities			5,371				1,857
Total current liabilities			17,609				18,287
Lease liabilities, noncurrent			39,857				58,623
Long-term debt, net of issuance costs			5,166				8,901
Other noncurrent liabilities			666				650
Total liabilities			63,298				86,461
Commitments and contingencies
Stockholders’ equity:
Series A common stock equivalent convertible preferred stock, $0.0001 par value; 7,000 shares authorized, 2,500 shares issued and outstanding at September 30, 2024 and December 31, 2023			-				-
Common stock, $0.0001 par value; 400,000,000 shares authorized, 2,507,171 and 2,460,772 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively			-				7
Additional paid-in capital			523,838				516,439
Accumulated other comprehensive gain			83				155
Accumulated deficit			(400,668	)			(337,595	)
Total stockholders’ equity			123,253				179,006
Total liabilities and stockholders’ equity		$	186,551			$	265,467

 

---

v3.24.3

Document and Entity Information	Nov. 12, 2024
Cover [Abstract]
Entity Registrant Name	Singular Genomics Systems, Inc.
Entity Central Index Key	0001850906
Document Type	8-K
Entity Information, Former Legal or Registered Name	N/A
Document Period End Date	Nov. 12, 2024
Amendment Flag	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Trading Symbol	OMIC
Entity File Number	001-40443
Entity Tax Identification Number	81-2948451
Entity Address, Address Line One	3010 Science Park Road
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	333-7830
Written Communications	false
Soliciting Material	false
Pre-commencement Issuer Tender Offer	false
Pre-commencement Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE

---